Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

Women's health brand opportunities infographic

Women turn to brands for health advice after feeling sidelined by professionals

Women want brands to provide more health information, representing huge opportunities for brands to advocate for their consumers.

Thrive Agency

- PMLiVE

Thriving, not surviving – a hybrid mentality

By Joanne Wunder

- PMLiVE

Novartis announces $300m investment to boost development of next-generation biotherapeutics

The multi-year investment will be implemented across the company’s existing locations in Switzerland, Slovenia and Austria

- PMLiVE

WHO announces new global fund for pandemic prevention and preparedness

Over $1.4bn in financial commitments have already been announced and more are expected in the coming months

- PMLiVE

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

CuraSen Therapeutics doses first patients with novel combination therapy in dementia study

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy shows promise for advanced biliary tract cancer

Updated results from a phase 3 trial showed the combination treatment reduced the risk of death by 24% versus chemotherapy alone

The Sofa Sessions – The Fifth Page

Page & Page Health

Medscape Education: An ESC to Remember

ESC 2022 is now a wrap! The Medscape team was on site with a booth on the exhibit floor, educational symposia, and a Tapas and Trends event where faculty shared...

Medscape Education

- PMLiVE

Creating strong employee engagement and retaining talent in the new normal

By Marie Little

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster receives CHMP recommendation

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Novartis and BeiGene announce positive phase 3 trial results for hepatocellular carcinoma treatment

Hepatocellular carcinoma accounts for 75-85% of liver cancer diagnoses

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvements for lung cancer patients

Data showed a confirmed objective response rate of 53.8% in patients with HER2-mutant metastatic non-small cell lung cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links